Capital Advantage’s Pfizer PFE Stock Holding History

Capital Advantage’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,187	Closed	-$234K	–	150
2025 Q3	$234K	Sell	9,187 -159	-2%	-$3.92K	0.04%	132
2025 Q2	$227K	Sell	9,346 -5,550	-37%	-$129K	0.04%	131
2025 Q1	$395K	Hold	14,896	–	–	0.07%	97
2024 Q4	$395K	Sell	14,896 -5,404	-27%	-$147K	0.07%	97
2024 Q3	$587K	Sell	20,300 -1,729	-8%	-$50.4K	0.11%	46
2024 Q2	$615K	Buy	22,029 +16	+0.1%	+$441	0.13%	41
2024 Q1	$626K	Sell	22,013 -232	-1%	-$6.44K	0.13%	41
2023 Q4	$640K	Sell	22,245 -2,825	-11%	-$85.4K	0.13%	35
2023 Q3	$832K	Buy	25,070 +508	+2%	+$18K	0.18%	34
2023 Q2	$876K	Sell	24,562 -235	-0.9%	-$9.15K	0.18%	34
2023 Q1	$1.01M	Buy	24,797 +883	+4%	+$38.1K	0.22%	33
2022 Q4	$1.23M	Sell	23,914 -73	-0.3%	-$3.5K	0.28%	29
2022 Q3	$1.05M	Buy	23,987 +1,951	+9%	+$94.8K	0.24%	32
2022 Q2	$1.16M	Sell	22,036 -797	-3%	-$40.6K	0.25%	31
2022 Q1	$1.18M	Buy	22,833 +791	+4%	+$41K	0.27%	31
2021 Q4	$1.19M	Buy	22,042 +506	+2%	+$25.1K	0.29%	30
2021 Q3	$926K	Buy	21,536 +45	+0.2%	+$1.99K	0.25%	30
2021 Q2	$842K	Sell	21,491 -12	-0.1%	-$467	0.22%	32
2021 Q1	$779K	Buy	21,503 +1,738	+9%	+$61.7K	0.21%	42
2020 Q4	$735K	Sell	19,765 -696	-3%	-$25.5K	0.22%	42
2020 Q3	$708K	Sell	20,461 -90	-0.4%	-$3.15K	0.23%	38
2020 Q2	$638K	Sell	20,551 -290	-1%	-$9.85K	0.23%	41
2020 Q1	$730K	Buy	20,841 +1,846	+10%	+$62.9K	0.29%	37
2019 Q4	$718K	Sell	18,995 -608	-3%	-$21.7K	0.23%	39
2019 Q3	$668K	Buy	+19,603	New	+$713K	0.23%	38
2019 Q1	$696K	Buy	17,276 +1,577	+10%	+$63.2K	0.25%	39
2018 Q4	$650K	Buy	15,699 +88	+0.6%	+$3.65K	0.25%	35
2018 Q3	$653K	Sell	15,611 -492	-3%	-$18.9K	0.15%	37
2018 Q2	$554K	Sell	16,103 -827	-5%	-$28.3K	0.13%	39
2018 Q1	$570K	Buy	16,930 +12	+0.1%	+$413	0.14%	38
2017 Q4	$581K	Buy	16,918 +11	+0.1%	+$375	0.15%	42
2017 Q3	$573K	Sell	16,907 -8,879	-34%	-$285K	0.14%	40
2017 Q2	$822K	Sell	25,786 -38	-0.1%	-$1.2K	0.22%	33
2017 Q1	$838K	Buy	25,824 +2,875	+13%	+$90.6K	0.23%	35
2016 Q4	$707K	Sell	22,949 -656	-3%	-$20K	0.2%	38
2016 Q3	$759K	Buy	23,605 +261	+1%	+$8.73K	0.21%	37
2016 Q2	$780K	Buy	23,344 +710	+3%	+$22.7K	0.23%	37
2016 Q1	$636K	Buy	22,634 +6,720	+42%	+$192K	0.23%	42
2015 Q4	$487K	Buy	15,914 +5	+0%	+$157	0.16%	49
2015 Q3	$474K	Buy	15,909 +1,242	+8%	+$39.8K	0.18%	47
2015 Q2	$467K	Sell	14,667 -417	-3%	-$13.6K	0.18%	43
2015 Q1	$498K	Buy	15,084 +5	+0%	+$159	0.2%	40
2014 Q4	$446K	Buy	15,079 +551	+4%	+$15.8K	0.18%	40
2014 Q3	$408K	Sell	14,528 -134	-0.9%	-$3.76K	0.21%	33
2014 Q2	$413K	Buy	14,662 +435	+3%	+$12.4K	0.23%	33
2014 Q1	$434K	Buy	14,227 +3,116	+28%	+$92.9K	0.3%	27
2013 Q4	$323K	Buy	+11,111	New	+$323K	0.22%	29

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Advantage's PFE Position: Q4 2025 in Review

Capital Advantage sold out of Pfizer (PFE) in Q4 2025, closing a stake of 9,187 shares — an estimated $234K sold.

Capital Advantage first reported a position in PFE in Q4 2013 and held it in 47 quarters. The position peaked at $1.23M in Q4 2022. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

Capital Advantage reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
Capital Advantage sold 9,187 Pfizer shares in Q4 2025, an estimated $234K.
Capital Advantage first reported a position in Pfizer in Q4 2013 and held it in 47 quarters.
Capital Advantage's Pfizer position peaked at $1.23M in Q4 2022.
2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Capital Advantage's 13F filing for Q4 2025, filed 7 Jan 2026.